Just spending the hols updating my research on Dimerix and I noticed on 7 June 2022 Dimerix announced (ASX release)
"an agreement with The Australian Centre for Accelerating Diabetes Innovations (ACADI) to progress DMX-200 into a new clinical trial in patients with diabetic kidney disease."
It was expected to be 12-24 months study of proteinuria and eGFR (kidney function), with an interim analysis, and was expected to commence Q4 2022.
Cant see any further info or anns. on this but may well have missed something.
Can anyone bring me up to date on this project.
cheers
Charalec
Dimerix (ASX: DXB) Discussion Thread, page-65
-
- There are more pages in this discussion • 576 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.5¢ |
Change
-0.015(2.78%) |
Mkt cap ! $288.8M | |||
| Open | High | Low | Value | Volume |
| 53.0¢ | 54.0¢ | 51.0¢ | $1.930M | 3.666M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 136 | 52.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.5¢ | 28650 | 2 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |